STD Panel

Most sexually transmitted infections do not announce themselves. Chlamydia, gonorrhea, syphilis, HIV, and herpes can all be present in your body for weeks, months, or even years without producing a single symptom. During that time, they can be passed to partners, and some can quietly damage your reproductive system, nervous system, or immune defenses. A single test for one infection misses the rest, and because having one STI raises your odds of carrying another, testing for just one gives you an incomplete and potentially dangerous picture.

This panel screens for five infections in a single visit using both blood and urine samples. It covers the bacterial infections that are curable if caught early, the viral infections that are manageable with early detection, and the one (HIV) where early treatment has turned a once fatal diagnosis into a condition with near-normal life expectancy. Together, these tests answer the question that matters most: am I carrying something I don't know about?

What This Panel Reveals

The panel covers three distinct categories of infection, each detected by a different type of test. Understanding what each category measures helps you interpret what a positive or negative result actually means for your body.

Active Bacterial Infections: Chlamydia and Gonorrhea

Chlamydia and gonorrhea are the two most commonly reported bacterial STIs. The CDC documented approximately 1.65 million chlamydia cases and over 648,000 gonorrhea cases in the United States in 2022, and those numbers represent only the cases that were actually diagnosed. These two infections are tested using nucleic acid amplification testing (NAAT), which detects the genetic material of the bacteria in a urine sample. NAAT is the gold standard for chlamydia and gonorrhea detection, with sensitivity above 95% for both organisms.

The reason screening matters so much for these two infections is that most people who carry them feel nothing. An estimated 70% of women and up to 50% of men with chlamydia have no symptoms at all. Gonorrhea follows a similar pattern, particularly in the cervix, throat, and rectum. Left untreated, chlamydia can cause pelvic inflammatory disease (PID) in roughly 10% to 15% of infected women, which can lead to chronic pain, ectopic pregnancy (a pregnancy that develops outside the uterus), or infertility. Both infections are fully curable with antibiotics when caught.

Syphilis Screening

Syphilis is tested through an RPR (Rapid Plasma Reagin) screen, a blood test that detects antibodies your immune system produces in response to tissue damage caused by the syphilis bacterium (Treponema pallidum). Syphilis cases in the US have surged in recent years, with reported cases increasing roughly 80% between 2018 and 2022. The initial sore (called a chancre) is painless and often hidden, which means the first stage frequently goes unnoticed.

Without treatment, syphilis progresses through stages. The early stages are easily treated with penicillin. But if it advances to the late stage, it can damage the heart, brain, and nervous system. The RPR screen has excellent sensitivity for secondary syphilis (near 100%) but is somewhat lower for very early primary syphilis (roughly 78% to 86%). A positive RPR always requires confirmatory testing with a second blood test that specifically detects the syphilis bacterium (called a treponemal test).

HIV Detection

This panel uses a fourth-generation HIV test, which detects both HIV antibodies (immune proteins your body makes in response to the virus) and the p24 antigen (a piece of the virus itself). By looking for the antigen in addition to antibodies, fourth-generation tests can identify HIV infection as early as two to four weeks after exposure, compared to the six to twelve weeks that older antibody-only tests required. The sensitivity of fourth-generation HIV testing exceeds 99.7%.

The panel also differentiates between HIV-1 (the most common type worldwide) and HIV-2 (found primarily in West Africa but present globally). This distinction matters because treatment regimens differ between the two types. An estimated 13% of people living with HIV in the United States do not know their status, and the CDC recommends that everyone between ages 13 and 64 be tested for HIV at least once, with more frequent testing for those at higher risk.

Herpes Antibody Status

The herpes tests in this panel measure IgG antibodies to herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) separately. IgG antibodies indicate whether you have ever been infected, not whether you are having an active outbreak right now. According to NHANES data from 2015 to 2016, approximately 48% of Americans aged 14 to 49 carry antibodies to HSV-1 (indicating past infection), and about 12% carry antibodies to HSV-2.

The type distinction is clinically meaningful. HSV-1 traditionally causes oral herpes but increasingly causes genital infections as well. HSV-2 is almost exclusively sexually transmitted and tends to reactivate more frequently when it infects the genital area. An estimated 80% to 90% of people with HSV-2 have never been formally diagnosed, because outbreaks can be mild, atypical, or entirely absent. Knowing your status helps you understand your risk of transmitting the virus and guides decisions about daily antiviral medication.

How to Read Your Results Together

A full STI panel is more informative than any single test because co-infections are common, and the presence of one infection changes the clinical significance of others. Here are the key patterns to look for.

One result that deserves special attention: if your chlamydia and gonorrhea tests are both positive, that is not uncommon. Co-infection with both bacteria occurs in roughly 10% to 40% of gonorrhea cases, depending on the population studied. Treatment protocols account for this, and most clinicians will treat both simultaneously.

When Results Can Be Misleading

Every test in this panel has a detection window, the period between exposure and the point when the test can reliably identify the infection. If you test too soon after a potential exposure, you may get a negative result despite being infected. NAAT for chlamydia and gonorrhea can detect infection within one to two weeks of exposure. The fourth-generation HIV test can detect infection in two to four weeks. RPR for syphilis typically becomes positive within three to six weeks after the initial sore appears. HSV IgG antibodies take the longest to develop, usually requiring at least three to four weeks, and in some people up to twelve weeks.

The RPR test can produce false positive results in certain conditions. Pregnancy, autoimmune diseases like lupus, recent vaccinations, and some chronic infections can trigger a positive RPR without actual syphilis infection. This is why a positive RPR screen always needs a confirmatory treponemal test. For herpes, the IgG blood test for HSV-1 has a higher false positive rate than HSV-2 testing when antibody levels are in the low-positive range, which is why equivocal results should be confirmed with a supplemental test.

Tracking Over Time

STI screening is not a one-time event. Your risk profile changes with new partners, and infections acquired between tests will only be caught by retesting. The CDC recommends annual chlamydia screening for all sexually active women under 25 and for older women with risk factors. Gonorrhea screening follows the same schedule in areas with high prevalence. Men who have sex with men should be screened for all five infections at least annually, and every three to six months if they have multiple partners.

For HIV, anyone at ongoing risk should test at least annually. If you are taking PrEP (a daily medication that prevents HIV), HIV testing every three months is standard. After a positive chlamydia or gonorrhea result that has been treated, retesting at three months is recommended because reinfection rates are high, roughly 10% to 20% within a few months of treatment.

Serial RPR testing also serves a specific purpose: after syphilis treatment, the RPR titer (a measure of antibody level) should decline over time. A rising titer after treatment suggests reinfection or treatment failure. Tracking your RPR over sequential draws gives your clinician a clear treatment response curve.

What to Do with Your Results

If every result is negative and you tested outside the window period for each infection, you can be reasonably confident you are not carrying any of these five infections at this time. Continue screening at regular intervals based on your risk factors.

If chlamydia or gonorrhea is positive, treatment is straightforward: antibiotics prescribed by any primary care clinician. Notify your sexual partners from the past 60 days so they can be tested and treated. If RPR is positive, get a confirmatory treponemal test before starting treatment. If confirmed, penicillin remains the standard therapy, and partner notification is essential.

A positive HIV result on a screening test requires a confirmatory test (typically an HIV-1/HIV-2 differentiation test). If confirmed, prompt connection with an HIV specialist is the single most important next step. Modern antiretroviral therapy (daily medication that controls the virus) can suppress HIV to undetectable levels, which means it cannot be transmitted sexually and life expectancy approaches that of someone without HIV. The earlier treatment begins, the better the outcomes.

For herpes, a positive HSV-2 IgG with a value above 3.5 is considered a reliable positive. Values between 1.1 and 3.5 are in a zone where false positives are more likely, and supplemental testing may be warranted. A positive result does not mean you need treatment unless you are having symptoms, planning a pregnancy, or trying to reduce transmission risk to a partner.